Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Varaphon Vongthavaravat, Bernardo L. Wajchenberg, Jorge N. Waitman, Joselynna A. Quimpo, Padmavathy S. Menon, Fethi Ben Khalifa & Weng-Ho Chow. (2002) An International Study of the Effects of Rosiglitazone plus Sulphonylurea in Patients with Type 2 Diabetes. Current Medical Research and Opinion 18:8, pages 456-461.
Read now
Read now
Scott L Grossman & Jan Lessem. (1997) Mechanisms and clinical effects of thiazolidinediones. Expert Opinion on Investigational Drugs 6:8, pages 1025-1040.
Read now
Read now
Articles from other publishers (30)
C. Janani & B.D. Ranjitha Kumari. (2015) PPAR gamma gene – A review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 9:1, pages 46-50.
Crossref
Crossref
Abhijit A. Ghadge, Shubhangi M. Harke, Suresh P. Khadke, Arundhati G. Diwan, Madhu Pankaj, Omkar P. Kulkarni, Prabhakar K. Ranjekar & Aniket A. Kuvalekar. (2014) Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: Desirable side-effects of antidiabetic drugs. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 8:4, pages 230-232.
Crossref
Crossref
E. Erdmann. (2006) Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. International Journal of Cardiology 107:2, pages 147-153.
Crossref
Crossref
Ekrem ORBAY, Mehmet SARGIN, Haluk SARGIN, Hülya GÖZÜ, Oya Uygur BAYRAMIÇLI & ALl YAYLA. (2004) Addition of Rosiglitazone to Glimepirid and Metformin Combination Therapy in Type 2 Diabetes. Endocrine Journal 51:6, pages 521-527.
Crossref
Crossref
Zachary Bloomgarden. 2004. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus
593
618
.
T. A. Jones, M. Sautter, L. F. Van Gaal & N. P. Jones. (2003) Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes, Obesity and Metabolism 5:3, pages 163-170.
Crossref
Crossref
X.-X. Zhu, C.-Y. Pan, G.-W. Li, H.-L. Shi, H. Tian, W.-Y. Yang, J. Jiang, X.-C. Sun, C. Davies & W.-H. Chow. (2003) Addition of Rosiglitazone to Existing Sulfonylurea Treatment in Chinese Patients with Type 2 Diabetes and Exposure to Hepatitis B or C. Diabetes Technology & Therapeutics 5:1, pages 33-42.
Crossref
Crossref
G Bakris, G Viberti, W M Weston, M Heise, L E Porter & M I Freed. (2003) Rosiglitazone reduces urinary albumin excretion in type II diabetes. Journal of Human Hypertension 17:1, pages 7-12.
Crossref
Crossref
Janice C Parker. (2002) Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Advanced Drug Delivery Reviews 54:9, pages 1173-1197.
Crossref
Crossref
Wei-Shiung Yang, Chi-Yuan Jeng, Ta-Jen Wu, Sachiyo Tanaka, Tohru Funahashi, Yuji Matsuzawa, Jao-Ping Wang, Chi-Ling Chen, Tong-Yuan Tai & Lee-Ming Chuang. (2002) Synthetic Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients. Diabetes Care 25:2, pages 376-380.
Crossref
Crossref
Antona J. Wagstaff & Karen L. Goa. (2002) Rosiglitazone. Drugs 62:12, pages 1805-1837.
Crossref
Crossref
C. Yang, T.-J. Chang, J.-C. Chang, M.-W. Liu, T.-Y. Tai, W. H. Hsu & L.-M. Chuang. (2001) Rosiglitazone (BRL 49653) Enhances Insulin Secretory Response via Phosphatidylinositol 3-Kinase Pathway. Diabetes 50:11, pages 2598-2602.
Crossref
Crossref
Byron J. Hoogwerf. (2001) POSTOPERATIVE MANAGEMENT OF THE DIABETIC PATIENT. Medical Clinics of North America 85:5, pages 1213-1228.
Crossref
Crossref
David E. Moller & Douglas A. Greene. 2001. Drug Discovery and Design. Drug Discovery and Design
181
212
.
B. H. R. Wolffenbuttel, R. Gomis, S. Squatrito, N. P. Jones & R. N. Patwardhan. (2001) Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabetic Medicine 17:1, pages 40-47.
Crossref
Crossref
Michiko Asano, Toshiaki Nakajima, Kuniaki Iwasawa, Toshihiro Morita, Fumitaka Nakamura, Hiroyuki Imuta, Keigo Chisaki, Nobuhiro Yamada, Masao Omata & Yukichi Okuda. (2009)
Troglitazone and pioglitazone attenuate agonist‐dependent Ca
2+
mobilization and cell proliferation in vascular smooth muscle cells
. British Journal of Pharmacology 128:3, pages 673-683.
Crossref
Crossref
Byron Hoogwerf & Rossana D. Danese. (1999) DRUG SELECTION AND THE MANAGEMENT OF CORTICOSTEROID-RELATED DIABETES MELLITUS. Rheumatic Disease Clinics of North America 25:3, pages 489-505.
Crossref
Crossref
EDWARD LIPKIN. (1999) New Strategies for the Treatment of Type 2. Journal of the American Dietetic Association 99:3, pages 329-334.
Crossref
Crossref
G?rard Emilien, Jean-Marie Maloteaux & Michel Ponchon. (1999) Pharmacological Management of Diabetes. Pharmacology & Therapeutics 81:1, pages 37-51.
Crossref
Crossref
Johannes Pill & Hans-Frieder Kühnle. (1999) BM 17.0744: A structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Metabolism 48:1, pages 34-40.
Crossref
Crossref
M.F. McCarty. (1998) Complementary measures for promoting insulin sensitivity in skeletal muscle. Medical Hypotheses 51:6, pages 451-464.
Crossref
Crossref
Li Sen Liu, Hideho Tanaka, Shinichi Ishii & Jürgen Eckel. (1998) The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes**This work was supported by the Ministerium für Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Bundesministerium für Gesundheit, EU COST Action B5, and a grant from Mitsubishi Chemical (Yokohama, Japan).. Endocrinology 139:11, pages 4531-4539.
Crossref
Crossref
L Pickavance, P S Widdowson, P King, S Ishii, H Tanaka & G Williams. (1998) The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. British Journal of Pharmacology 125:4, pages 767-770.
Crossref
Crossref
Shota Ikeda & Toshifumi Watanabe. (1998) Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes. European Journal of Pharmacology 357:2-3, pages 243-250.
Crossref
Crossref
Zachary T. Bloomgarden. (1998) Troglitazone: Current Therapeutic Role in Type 2 Diabetes Mellitus. Endocrine Practice 4:4, pages 213-218.
Crossref
Crossref
Michael D Johnson, Lance K Campbell & R Keith Campbell. (2016) Troglitazone: Review and Assessment of Its Role in the Treatment of Patients with Impaired Glucose Tolerance and Diabetes Mellitus. Annals of Pharmacotherapy 32:3, pages 337-348.
Crossref
Crossref
Zachary T. Bloomgarden. (1998) Insulin resistance: current concepts. Clinical Therapeutics 20:2, pages 216-231.
Crossref
Crossref
JAMES E. FOLEY, ROBERT C. ANDERSON, PHILIP A. BELL, BRYAN F. BURKEY, RHONDA O. DEEMS, CHRISTOPHER de SOUZA & BETH E. DUNNING. (1997) Pharmacological Strategies for Reduction of Lipid Availability. Annals of the New York Academy of Sciences 827:1 Lipids and Sy, pages 231-245.
Crossref
Crossref
David J. Schneider & Burton E. Sobel. (2009) Determinants of coronary vascular disease in patients with type ii diabetes mellitus and their therapeutic implications. Clinical Cardiology 20:5, pages 433-440.
Crossref
Crossref
Kevin Lee, Tim Ibbotson, Peter J. Richardson & Philip R. Boden. (1996) Inhibition of KATP channel activity by troglitazone in CRI-G1 insulin-secreting cells. European Journal of Pharmacology 313:1-2, pages 163-167.
Crossref
Crossref